Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Revvity Omics, |
RCV003138619 | SCV003824542 | uncertain significance | not provided | 2021-09-06 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003410276 | SCV004107773 | uncertain significance | SPECC1L-related disorder | 2023-06-09 | criteria provided, single submitter | clinical testing | The SPECC1L c.362C>T variant is predicted to result in the amino acid substitution p.Ser121Phe. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0029% of alleles in individuals of Latino descent in gnomAD (http://gnomad.broadinstitute.org/variant/22-24717310-C-T). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Labcorp Genetics |
RCV003138619 | SCV004272597 | likely benign | not provided | 2024-03-20 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004246061 | SCV004955420 | uncertain significance | Inborn genetic diseases | 2023-12-18 | criteria provided, single submitter | clinical testing | The c.362C>T (p.S121F) alteration is located in exon 5 (coding exon 3) of the SPECC1L gene. This alteration results from a C to T substitution at nucleotide position 362, causing the serine (S) at amino acid position 121 to be replaced by a phenylalanine (F). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |